Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Clarivate Analytics – a Powerhouse in IP assets and in Pharmaceuticals Informercials

Curator and Reporter: Aviva Lev-Ari, PhD, RN

We addressed in the past in several articles the emergence of Clarivate in its new life post Reuters years which ended by a SPAC IPO in 2019. This articles included:

• Clarivate Analytics expanded IP data leadership by new acquisition of the leading provider of intellectual property case law and analytics Darts-ip

https://pharmaceuticalintelligence.com/2019/12/02/clarivate-analytics-expanded-ip-data-leadership-by-new-acquisition-of-the-leading-provider-of-intellectual-property-case-law-and-analytics-darts-ip/

• Innovation and Patent Activity during COVID-19 from Clarivate – Survey Results Published

https://pharmaceuticalintelligence.com/2020/06/30/innovation-and-patent-activity-during-covid-19-from-clarivate-survey-result-published/

• Chasing change: Innovation and patent activity during COVID-19

https://pharmaceuticalintelligence.com/2020/07/02/chasing-change-innovation-and-patent-activity-during-covid-19/

• Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class

 https://pharmaceuticalintelligence.com/2019-vista/potential-use-of-lpbi-ip-as-value-price-driver-by-potential-acquirer-assumptions-per-asset-class/

• AI Acquisitions by Big Tech Firms Are Happening at a Blistering Pace: 2019 Recent Data by CBI Insights

https://pharmaceuticalintelligence.com/2019/12/11/ai-acquisitions-by-big-tech-firms-are-happening-at-a-blistering-pace-2019-recent-data-by-cbiinsights/

• WHAT ARE LPBI Group’s NEEDS in June 2019 – Aviva’s BOLD VISION on June 11, 2019

https://pharmaceuticalintelligence.com/2019-vista/what-are-lpbi-groups-needs-in-june-2019-avivas-bold-vision-on-june-11-2019/

• Opportunities Map for LPBI Group’s three Intellectual Property Asset Classes of Digital Published Products in the Acquisition Arena

https://pharmaceuticalintelligence.com/2019-vista/opportunities-map-in-the-acquisition-arena/

• Multiple Major Scientific Journals Will Fully Adopt Open Access Under Plan S

https://pharmaceuticalintelligence.com/2020/09/10/multiple-major-scientific-journals-will-fully-adopt-open-access-under-plan-s/

 

In this curation I wish to showcase Clarivate as a result of a successful SPAC as presented in Financial Times article

The Spac sponsor bonanza

Ortenca Aliaj and Sujeet Indap in New York and Miles Kruppa in San Francisco

 NOVEMBER 13 2020

https://www.ft.com/content/9b481c63-f9b4-4226-a639-238f9fae4dfc

Few have replicated Mr Klein’s success, which he achieved after using a Spac to take the data company Clarivate Analytics public in 2019

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/9b481c63-f9b4-4226-a639-238f9fae4dfc

That moment in June in which Mr Klein and his partners cashed in more than $60m came after the stock had doubled to more than $20, in part thanks to a deal to buy the intellectual property management and technology company CPA Global. Onex and Barings, the two private equity firms that owned Clarivate before it went public via Mr Klein’s Spac, also sold stock at the same time.

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found here.
https://www.ft.com/content/9b481c63-f9b4-4226-a639-238f9fae4dfc

Clarivate’s share price has since risen to $27.69, so the value of Mr Klein’s remaining stake has continued to swell and his investor group still holds shares worth $395m. The group also has separate warrants on top further augmenting their potential profit.

See Figure 

SPAC IPO, 11/2018, $10/share

–>>> Merger, 3/2019, $10/share

–>>>Clarivate PLC, 11/2020, $27/share

… asymmetry of Spac mathematics: the risk in Spacs falls most heavily on outside shareholders even as the return on investment for sponsors looks very promising indeed.

SOURCE

https://www.ft.com/content/9b481c63-f9b4-4226-a639-238f9fae4dfc

 

It worth exploring the synergies embedded in a potential acquisition of LPBI Groups Portfolio of IP Assets by Clarivate Analytics, a publishing company that has the infrastructure needed for promotion of LPBI Group’s content in Pharmaceutical Media, Medicine, Life Sciences and Health care and for Monetization of this content.

Portfolio of IP Assets